AVAngel Loza Valdes

Angel Loza Valdes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angel Loza Valdes has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Triazolo[4,5-d]pyrimidin-5-amines based ERK3 inhibitors fail to demonstrate selective effects on adipocyte function

    by Andrei Belykh, Izabela Hawro, Katarzyna Kolczyńska-Matysiak, Angel Loza-Valdes, Adam Mieczkowski, Grzegorz Sumara


  • Open Access

    Platelet‐derived lipids promote insulin secretion of pancreatic β cells

    by Till Karwen, Katarzyna Kolczynska‐Matysiak, Carina Gross, Mona C Löffler, Mike Friedrich, Angel Loza‐Valdes, Werner Schmitz, Magdalena Wit, Filip Dziaczkowski, Andrei Belykh, et al.

    Hyperreactive platelets are commonly observed in diabetic patients indicating a potential link between glucose homeostasis and platelet reactivity. This raises the possibility that platelets may play a role in the regulation of metabolism. Pancreatic β cells are the central regulators of systemic glucose homeostasis. Here, we show that factor(s) derived from β cells stimulate platelet activity and platelets selectively localize to the vascular endothelium of pancreatic islets. Both depletion of platelets and ablation of major platelet adhesion or activation pathways consistently resulted in impaired glucose tolerance and decreased circulating insulin levels. Furthermore, we found platelet‐derived lipid classes to promote insulin secretion and identified 20‐Hydroxyeicosatetraenoic acid (20‐HETE) as the main factor promoting β cells function. Finally, we demonstrate that the levels of platelet‐derived 20‐HETE decline with age and that this parallels with reduced impact of platelets on β cell function. Our findings identify an unexpected function of platelets in the regulation of insulin secretion and glucose metabolism, which promotes metabolic fitness in young individuals.


  • Open Access

    A phosphoproteomic approach reveals that PKD3 controls PKA-mediated glucose and tyrosine metabolism

    by Angel Loza-Valdes, Alexander E Mayer, Toufic Kassouf, Jonathan Trujillo-Viera, Werner Schmitz, Filip Dziaczkowski, Michael Leitges, Andreas Schlosser, Grzegorz Sumara

    Members of the protein kinase D (PKD) family (PKD1, 2, and 3) integrate hormonal and nutritional inputs to regulate complex cellular metabolism. Despite the fact that a number of functions have been annotated to particular PKDs, their molecular targets are relatively poorly explored. PKD3 promotes insulin sensitivity and suppresses lipogenesis in the liver of animals fed a high-fat diet. However, its substrates are largely unknown. Here we applied proteomic approaches to determine PKD3 targets. We identified more than 300 putative targets of PKD3. Furthermore, biochemical analysis revealed that PKD3 regulates cAMP-dependent PKA activity, a master regulator of the hepatic response to glucagon and fasting. PKA regulates glucose, lipid, and amino acid metabolism in the liver, by targeting key enzymes in the respective processes. Among them the PKA targets phenylalanine hydroxylase (PAH) catalyzes the conversion of phenylalanine to tyrosine. Consistently, we showed that PKD3 is activated by glucagon and promotes glucose and tyrosine levels in hepatocytes. Therefore, our data indicate that PKD3 might play a role in the hepatic response to glucagon.


  • Open Access

    Protein Kinase D2 drives chylomicron‐mediated lipid transport in the intestine and promotes obesity

    by Jonathan Trujillo‐Viera, Rabih El‐Merahbi, Vanessa Schmidt, Till Karwen, Angel Loza‐Valdes, Akim Strohmeyer, Saskia Reuter, Minhee Noh, Magdalena Wit, Izabela Hawro, et al.

    Lipids are the most energy‐dense components of the diet, and their overconsumption promotes obesity and diabetes. Dietary fat content has been linked to the lipid processing activity by the intestine and its overall capacity to absorb triglycerides (TG). However, the signaling cascades driving intestinal lipid absorption in response to elevated dietary fat are largely unknown. Here, we describe an unexpected role of the protein kinase D2 (PKD2) in lipid homeostasis. We demonstrate that PKD2 activity promotes chylomicron‐mediated TG transfer in enterocytes. PKD2 increases chylomicron size to enhance the TG secretion on the basolateral side of the mouse and human enterocytes, which is associated with decreased abundance of APOA4. PKD2 activation in intestine also correlates positively with circulating TG in obese human patients. Importantly, deletion, inactivation, or inhibition of PKD2 ameliorates high‐fat diet‐induced obesity and diabetes and improves gut microbiota profile in mice. Taken together, our findings suggest that PKD2 represents a key signaling node promoting dietary fat absorption and may serve as an attractive target for the treatment of obesity.


  • Top Cited Papers
    Open Access

    Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review

    by Katarzyna Kolczynska, Angel Loza-Valdes, Izabela Hawro, Grzegorz Sumara

    Protein kinase C (PKC) and Protein kinase D (PKD) isoforms can sense diacylglycerol (DAG) generated in the different cellular compartments in various physiological processes. DAG accumulates in multiple organs of the obese subjects, which leads to the disruption of metabolic homeostasis and the development of diabetes as well as associated diseases. Multiple studies proved that aberrant activation of PKCs and PKDs contributes to the development of metabolic diseases. DAG-sensing PKC and PKD isoforms play a crucial role in the regulation of metabolic homeostasis and therefore might serve as targets for the treatment of metabolic disorders such as obesity and diabetes.


  • Open Access

    The adrenergic-induced ERK3 pathway drives lipolysis and suppresses energy dissipation

    by Rabih El-Merahbi, Jonathan Trujillo Viera, Angel Loza Valdes, Katarzyna Kolczynska, Saskia Reuter, Mona C. Löffler, Manuela Erk, Carsten P. Ade, Till Karwen, Alexander E. Mayer, et al.

    Obesity-induced diabetes affects >400 million people worldwide. Uncontrolled lipolysis (free fatty acid release from adipocytes) can contribute to diabetes and obesity. To identify future therapeutic avenues targeting this pathway, we performed a high-throughput screen and identified the extracellular-regulated kinase 3 (ERK3) as a hit. We demonstrated that β-adrenergic stimulation stabilizes ERK3, leading to the formation of a complex with the cofactor MAP kinase-activated protein kinase 5 (MK5), thereby driving lipolysis. Mechanistically, we identified a downstream target of the ERK3/MK5 pathway, the transcription factor FOXO1, which promotes the expression of the major lipolytic enzyme ATGL. Finally, we provide evidence that targeted deletion of ERK3 in mouse adipocytes inhibits lipolysis, but elevates energy dissipation, promoting lean phenotype and ameliorating diabetes. Thus, ERK3/MK5 represents a previously unrecognized signaling axis in adipose tissue and an attractive target for future therapies aiming to combat obesity-induced diabetes.


  • The kinase PKD3 provides negative feedback on cholesterol and triglyceride synthesis by suppressing insulin signaling

    by Alexander E. Mayer, Mona C. Löffler, Angel E. Loza Valdés, Werner Schmitz, Rabih El-Merahbi, Jonathan Trujillo Viera, Manuela Erk, Thianzhou Zhang, Ursula Braun, Mathias Heikenwalder, et al.

    PKD3 prevents triglyceride and cholesterol accumulation in the liver in response to insulin.


  • Protein kinase D1 deletion in adipocytes enhances energy dissipation and protects against adiposity

    by Mona C Löffler, Alexander E Mayer, Jonathan Trujillo Viera, Angel Loza Valdes, Rabih El‐Merahbi, Carsten P Ade, Till Karwen, Werner Schmitz, Anja Slotta, Manuela Erk, et al.

    Nutrient overload in combination with decreased energy dissipation promotes obesity and diabetes. Obesity results in a hormonal imbalance, which among others activates G protein‐coupled receptors utilizing diacylglycerol (DAG) as secondary messenger. Protein kinase D1 (PKD1) is a DAG effector, which integrates multiple nutritional and hormonal inputs, but its physiological role in adipocytes is unknown. Here, we show that PKD1 promotes lipogenesis and suppresses mitochondrial fragmentation, biogenesis, respiration, and energy dissipation in an AMP‐activated protein kinase (AMPK)‐dependent manner. Moreover, mice lacking PKD1 in adipocytes are resistant to diet‐induced obesity due to elevated energy expenditure. Beiging of adipocytes promotes energy expenditure and counteracts obesity. Consistently, deletion of PKD1 promotes expression of the β3‐adrenergic receptor (ADRB3) in a CCAAT/enhancer binding protein (C/EBP)‐α‐ and δ‐dependent manner, which leads to the elevated expression of beige markers in adipocytes and subcutaneous adipose tissue. Finally, deletion of PKD1 in adipocytes improves insulin sensitivity and ameliorates liver steatosis. Thus, depletion of PKD1 in adipocytes increases energy dissipation by several complementary mechanisms and might represent an attractive strategy to treat obesity and its related complications. Synopsis Nutrient overload results in hormone imbalance and activation of DAG‐dependent signaling cascades including protein kinase D1 (PKD1). Here, mouse models reveal a causal role for PKD1 in controlling mitochondrial metabolism and lipid accumulation in fat cells, promoting obesity and diabetes. PKD1 drives lipogenesis by inhibiting AMPK. PKD1 inhibits mitochondrial fragmentation and respiration in adipocytes. PKD1 suppresses C/EBP‐α/δ‐dependent transcription of β3 adrenergic receptor and beige adipocyte markers. Deletion of PKD1 in adipocytes protects mice from obesity, type 2 diabetes and liver steatosis in vivo.


  • Open Access

    Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice

    by Jean-Mathieu Berger, Angel Loza Valdes, Jesper Gromada, Norma Anderson, Jay D. Horton


  • Open Access

    Hypoxia-Inducible Lipid Droplet–Associated Is Not a Direct Physiological Regulator of Lipolysis in Adipose Tissue

    by Wieneke Dijk, Frits Mattijssen, Montserrat de la Rosa Rodriguez, Angel Loza Valdes, Anne Loft, Susanne Mandrup, Eric Kalkhoven, Ling Qi, Jan Willem Borst, Sander Kersten

    Triglycerides are stored in specialized organelles called lipid droplets. Numerous proteins have been shown to be physically associated with lipid droplets and govern their function. Previously, the protein hypoxia-inducible lipid droplet–associated (HILPDA) was localized to lipid droplets and was suggested to inhibit triglyceride lipolysis in hepatocytes. We confirm the partial localization of HILPDA to lipid droplets and show that HILPDA is highly abundant in adipose tissue, where its expression is controlled by the peroxisome proliferator–activated receptor γ and by β-adrenergic stimulation. Levels of HILPDA markedly increased during 3T3-L1 adipocyte differentiation. Nevertheless, silencing of Hilpda using small interfering RNA or overexpression of Hilpda using adenovirus did not show a clear impact on 3T3-L1 adipogenesis. Following β-adrenergic stimulation, the silencing of Hilpda in adipocytes did not significantly alter the release of nonesterified fatty acids (NEFA) and glycerol. By contrast, adenoviral-mediated overexpression of Hilpda modestly attenuated the release of NEFA from adipocytes following β-adrenergic stimulation. In mice, adipocyte-specific inactivation of Hilpda had no effect on plasma levels of NEFA and glycerol after fasting, cold exposure, or pharmacological β-adrenergic stimulation. In addition, other relevant metabolic parameters were unchanged by adipocyte-specific inactivation of Hilpda. Taken together, we find that HILPDA is highly abundant in adipose tissue, where its levels are induced by peroxisome proliferator–activated receptor γ and β-adrenergic stimulation. In contrast to the reported inhibition of lipolysis by HILPDA in hepatocytes, our data do not support an important direct role of HILPDA in the regulation of lipolysis in adipocytes in vivo and in vitro.